Sun Pharma Says Ahmednagar Fire Will Not Affect Production
Sun Pharma said a fire that left two dead at the company’s Ahmednagar, India factory did not affect production.
Sun Pharma says there was no loss of production at the company’s Ahmednagar, India factory after a fire broke out on Dec. 28, 2016. In a letter to the Bombay Stock Exchange (BSE) Sun Pharma reported two employees succumbed to burn-related injuries resulting from the fire. Two additional employees are being treated at a local hospital. The company said that the cause of the fire is under investigation with the assistance of local law enforcement, and there was no loss of production at the facility.
“We stand by the families of these four workmen in this hour of distress and will look into providing all kind of support as necessary,”Ashook I Bhuta, compliance officer, at Sun Pharma wrote in the letter to BSE. “We are currently investigating the matter with the help of local law enforcement. There is no loss of production at Ahmednagar factory on account of this incident.”
Source: BSE
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
